Xortx announces presentation at the rare and genetic disease summit

Calgary, alberta, dec. 12, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a presentation by dr. allen davidoff at the rare and genetic kidney disease summit, in boston, massachusetts at 10:30 am et, thursday december 12, 2024. the presentation entitled “autosomal dominant polycystic kidney disease - genetic and environmental factors → evidence for aberrant purine metabolism as a second hit determining disease progression.”
XRTX Ratings Summary
XRTX Quant Ranking